Influence of tumor cell proliferation and sex-hormone receptors on effectiveness of radiation therapy for dogs with incompletely resected meningiomas

Théon, Alain P; Lecouteur, Richard A; Carr, Elizabeth A.; Griffey, Stephen M.

doi:10.2460/javma.2000.216.701

Cited by 59 publications

(72 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This finding seems to support the fact that metalloproteinase activity is not that strictly related to the proliferative index of neoplastic meningial cells, as conversely demonstrated for PR88. 25,46 The follow-up data showed a survival time of up to 58 months for feline meningiomas submitted to surgery and for canine meningiomas of up to 32 months, even though they were malignant. These findings are more encouraging than those reported in the literature.…”

Section: Discussionmentioning

confidence: 99%

“…It has been reported that a high proliferative index in the tumor is associated with low progesterone receptor (PR) concentration, suggesting that PR expression in canine and feline meningiomas is a reliable prognostic factor in the evaluation of this tumor, as well as in humans. 2,12,25,46 More recently, canine and feline meningiomas have been tested for telomerase immunoreactivity 22,26 and have produced contradictory results as to the correlation with the proliferative index.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Matrix Metalloproteinase-2 and Matrix Metalloproteinase-9 Expression in Canine and Feline Meningioma

et al. 2009

View full text Add to dashboard Cite

Abstract. Fifty-one meningiomas obtained from 28 dogs and 23 cats were selected for this study to investigate the immunohistochemical expression of matrix metalloproteinase (MMP)-2 and MMP-9 and to compare it to the reverse transcriptase subunit of human-telomerase, progesterone receptor expression, and the proliferative index of the tumors, expressed by Ki67 and proliferating cellular nuclear antigen. Paraffin-embedded tumor tissue was obtained from biopsy samples (28 cases) and at necropsy (23 cases). The most common histotype was malignant in dogs (12/28) and transitional in cats (12/23). Slides immunolabelled for MMPs showed a diffuse cytoplasmic pattern. Twenty-one cases (19 dogs and 2 cats) did not express MMP-2, while only 2 cases were completely negative for MMP-9. The highest values of MMP-2 and MMP-9 were observed in a psammomatous and meningothelial tumor, respectively. On statistical analysis, MMP-2 expression did not show a significant correlation with MMP-9. Moreover, both MMP expressions failed to show significant variance among histologic patterns of the tumor and correlation with the proliferative index. MMP immunolabeling showed an inconstant correlation with progesterone receptor expression. No significant correlation was found between MMP and reverse transcriptase subunit of human-telomerase expression. In feline meningiomas, the MMP-2 value was significantly higher than in canine tumors and the MMP-9 value tended to be low for meningiomas with a follow-up duration from the 23 rd month to the 44 th month. In cats, the longer the time from surgery, the lower the proliferative index seemed to be. In dogs, we failed to find a correlation between MMP expression and the follow-up duration.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Matrix Metalloproteinase-2 and Matrix Metalloproteinase-9 Expression in Canine and Feline Meningioma

et al. 2009

View full text Add to dashboard Cite

show abstract

“…Similar to human brain tumors, overexpression of cellular proliferation and apoptosis‐associated markers such as EGFR, PDGFRa, VEGFR1,2, c‐Met, IGFBP2,108, 109, 110, 111 c‐erbB2, pERK, pAkt, Bcl‐2, Bcl‐xL,111 and the angiogenic factor VEGF112, 113, 114, 115, 116 has been reported in both canine gliomas and meningiomas. Decreased progesterone receptor expression has been reported in canine meningiomas associated with higher proliferative indices and poorer prognosis,117, 118 and these features also are associated with increased VEGF expression 114…”

Section: Molecular Diagnosticsmentioning

confidence: 99%

“…Currently available studies highlight the large variation in outcome, and the potential impact of applied technology. In dogs with confirmed meningiomas, standard surgical cytoreduction alone generally has been reported to result in median survival times of approximately 4.5–7 months,144, 145, 146 with an improvement in median survival to 16.5–30 months with adjunctive radiation therapy 118, 145. However, use of cortical resection, ultrasonic aspiration, or endoscope‐assisted techniques has been reported to result in median survival times of 16, 41, and 70 months, respectively, for rostrotentorial meningiomas 146, 147, 148.…”

Section: Surgical Treatmentmentioning

confidence: 99%

Advances in Diagnostic and Treatment Modalities for Intracranial Tumors

Dickinson

2014

Veterinary Internal Medicne

View full text Add to dashboard Cite

Intracranial neoplasia is a common clinical condition in domestic companion animals, particularly in dogs. Application of advances in standard diagnostic and therapeutic modalities together with a broad interest in the development of novel translational therapeutic strategies in dogs has resulted in clinically relevant improvements in outcome for many canine patients. This review highlights the status of current diagnostic and therapeutic approaches to intracranial neoplasia and areas of novel treatment currently in development.

show abstract

“…11 Markers used in meningiomas of domestic species include cytokeratins, estrogen receptor, glial fibrillary acidic protein (GFAP), Ki67, neuron-specific enolase, progesterone receptor, proliferating cell nuclear antigen, S100, synaptophysin, h-telomerase, and vimentin. 1,3,27,28,42,59 Combining the results of 2 large series of canine meningiomas, vimentin was expressed in all (37 of 37), followed by neuron-specific enolase (29 of 37), S100 (28 of 37), GFAP (6 of 37), and cytokeratins (11 of 37). Synaptophysin was not reactive in any case (0 of 15).…”

mentioning

confidence: 99%

Immunohistochemical Detection of CD34, E-cadherin, Claudin-1, Glucose Transporter 1, Laminin, and Protein Gene Product 9.5 in 28 Canine and 8 Feline Meningiomas

et al. 2010

View full text Add to dashboard Cite

The variation in histologic pattern of meningiomas can make their diagnosis challenging. The immunohistochemical profile of 28 canine and 8 feline meningiomas was examined. Tumor types included anaplastic (6 dogs), angiomatoid (1 cat), fibroblastic (3 dogs, 1 cat), meningothelial (1 dog), microcystic (2 dogs), myxoid (3 dogs), psammomatous (4 cats), and transitional (13 dogs, 2 cats). The authors compared the expression of novel markers (CD34, E-cadherin, claudin-1, glucose transporter 1 [GLUT-1], laminin, and protein gene product [PGP] 9.5) with published markers (cytokeratins, glial fibrillary acidic protein [GFAP], progesterone receptor, S100, and vimentin). Neoplastic cells were immunohistochemically positive for vimentin in 100% of the meningiomas; CD34, 94%; GLUT-1, 86%; E-cadherin, 81%; S100, 75%; laminin, 72%; claudin-1, 60%; PGP 9.5, 55%; progesterone receptor, 44%; pancytokeratins, 39%; cytokeratins 8/18, 17%, and GFAP in 9%. Ki67 index did not correlate well with mitotic index. Based on these results and those in the human literature, immunohistochemistry for vimentin, CD34, and E-cadherin is proposed to support a diagnosis of meningioma. Immunohistochemistry for claudin-1, albeit of only moderate to low sensitivity in canine and feline meningiomas, may help to distinguish meningioma from some mesenchymal neoplasms involving the brain and associated structures, such as schwannomas, which in humans express claudin-1 poorly or not at all. Further studies with CD34, E-cadherin, and claudin-1 in canine and feline tumors that may mimic meningiomas are needed to determine the adequacy of this approach.

show abstract

Influence of tumor cell proliferation and sex-hormone receptors on effectiveness of radiation therapy for dogs with incompletely resected meningiomas

Cited by 59 publications

References 42 publications

Matrix Metalloproteinase-2 and Matrix Metalloproteinase-9 Expression in Canine and Feline Meningioma

Matrix Metalloproteinase-2 and Matrix Metalloproteinase-9 Expression in Canine and Feline Meningioma

Advances in Diagnostic and Treatment Modalities for Intracranial Tumors

Immunohistochemical Detection of CD34, E-cadherin, Claudin-1, Glucose Transporter 1, Laminin, and Protein Gene Product 9.5 in 28 Canine and 8 Feline Meningiomas

Contact Info

Product

Resources

About